NO323155B1 - Makrofagaktiverende faktorer avledet fra klonet vitamin D-bindingsprotein - Google Patents

Makrofagaktiverende faktorer avledet fra klonet vitamin D-bindingsprotein Download PDF

Info

Publication number
NO323155B1
NO323155B1 NO19975771A NO975771A NO323155B1 NO 323155 B1 NO323155 B1 NO 323155B1 NO 19975771 A NO19975771 A NO 19975771A NO 975771 A NO975771 A NO 975771A NO 323155 B1 NO323155 B1 NO 323155B1
Authority
NO
Norway
Prior art keywords
cloned
protein
cancer
cells
macrophage
Prior art date
Application number
NO19975771A
Other languages
English (en)
Norwegian (no)
Other versions
NO975771D0 (no
NO975771L (no
Inventor
Nobuto Yamamoto
Original Assignee
Nobuto Yamamoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/478,121 external-priority patent/US5620846A/en
Application filed by Nobuto Yamamoto filed Critical Nobuto Yamamoto
Publication of NO975771D0 publication Critical patent/NO975771D0/no
Publication of NO975771L publication Critical patent/NO975771L/no
Publication of NO323155B1 publication Critical patent/NO323155B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
NO19975771A 1995-06-07 1997-12-08 Makrofagaktiverende faktorer avledet fra klonet vitamin D-bindingsprotein NO323155B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/478,121 US5620846A (en) 1995-06-07 1995-06-07 Diagnostic and prognostic indices for cancer and aids
US08/618,485 US6410269B1 (en) 1995-06-07 1996-03-19 Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
PCT/US1996/008867 WO1996040903A1 (en) 1995-06-07 1996-06-05 Macrophage activating factors derived from cloned vitamin d binding protein

Publications (3)

Publication Number Publication Date
NO975771D0 NO975771D0 (no) 1997-12-08
NO975771L NO975771L (no) 1998-01-30
NO323155B1 true NO323155B1 (no) 2007-01-08

Family

ID=27045792

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975771A NO323155B1 (no) 1995-06-07 1997-12-08 Makrofagaktiverende faktorer avledet fra klonet vitamin D-bindingsprotein

Country Status (12)

Country Link
US (3) US6410269B1 (enExample)
EP (3) EP0837932B1 (enExample)
JP (1) JPH11511962A (enExample)
CN (2) CN1510147A (enExample)
AT (1) ATE307885T1 (enExample)
AU (1) AU6253596A (enExample)
BR (1) BR9609072A (enExample)
CA (1) CA2223940A1 (enExample)
DE (2) DE69635346D1 (enExample)
ES (1) ES2252756T3 (enExample)
NO (1) NO323155B1 (enExample)
WO (1) WO1996040903A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985545A (en) * 1996-03-19 1999-11-16 Yamamoto; Nobuto Diagnostic and prognostic ELISA assays of serum α-N-acetylgalactosaminidase for AIDS
WO2001085194A1 (en) * 2000-05-09 2001-11-15 Children's Medical Center Corporation Method and composition for the treatment of angiogenesis
US20050009120A1 (en) * 2000-09-07 2005-01-13 The Brigham And Women's Hospital, Inc. Methods of detecting ovarian cancer based on osteopontin
US6846642B2 (en) * 2000-09-07 2005-01-25 The Brigham And Women's Hospital, Inc. Methods of detecting cancer based on prostasin
EP1347953A2 (en) * 2000-11-09 2003-10-01 Northeastern Ohio Universities College of Medicine Agents and methods for promoting bone growth
US20020164664A1 (en) * 2000-11-30 2002-11-07 Matritech, Inc. Detection and treatment of prostate cancer
US7112408B2 (en) * 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US6806355B2 (en) 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
US7288383B2 (en) * 2003-01-15 2007-10-30 The Brigham And Women's Hospital, Inc. Eosinophil-derived neurotoxin as a marker for ovarian cancer
WO2005087793A2 (en) * 2004-02-05 2005-09-22 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2006063028A2 (en) * 2004-12-07 2006-06-15 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
US8460697B2 (en) 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US8496942B2 (en) 2006-12-13 2013-07-30 Susavion Biosciences, Inc. Therapeutic peptides and uses thereof
US7811995B2 (en) 2006-12-13 2010-10-12 Susavion Biosciences, Inc. Therapeutic and diagnostic peptides
USRE46425E1 (en) 2006-12-13 2017-06-06 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US7838497B2 (en) 2006-12-13 2010-11-23 Susavion Biosciences, Inc. Pro-angiogenic peptides
US20110123591A1 (en) * 2009-08-22 2011-05-26 Charles Knezevich Tumoricidal, bactericidal, or viricidal macrophage activation
WO2012029954A1 (ja) 2010-09-03 2012-03-08 国立大学法人徳島大学 新規Ｇｃグロブリンガラクトース脱糖体の製造方法
EP2694088B1 (en) * 2011-04-07 2017-06-07 Efranat Ltd. Macrophage activating factor for pharmaceutical compositions
EP2561879A1 (en) 2011-08-23 2013-02-27 Protea Biopharma N.V. Macrophage activating factor for use in the treatment of chronic fatigue syndrome (CFS) and CFS-related diseases and disorders
WO2013130953A2 (en) * 2012-03-01 2013-09-06 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
EP2687264A1 (en) 2012-07-17 2014-01-22 Protea Biopharma N.V. Macrophage Activating Factor for treatment of endometriosis
AU2014207429B2 (en) * 2013-01-18 2018-11-01 Ellis KLINE Selective glycosidase regimen for immune programming and treatment of cancer
CN105530950A (zh) * 2013-06-09 2016-04-27 艾弗兰纳特有限公司 包含Gc-巨噬细胞活化因子的组合物及其用途
AT518622A1 (de) * 2016-04-21 2017-11-15 Hg Pharma Gmbh Dimerer Komplex aus selektiv deglycosyliertem Vitamin D bindenden Protein (GcMAF) und Cholecalciferol (Calciol) und Verfahren zu dessen Herstellung
WO2019117295A1 (ja) * 2017-12-15 2019-06-20 公益財団法人神戸医療産業都市推進機構 活性型ＧｃＭＡＦの製造方法
EP4260866A4 (en) 2020-12-08 2025-01-01 Saisei Pharma Co., Ltd. MACROPHAGE ACTIVATOR
CN118325844B (zh) * 2023-09-07 2025-01-03 武汉奥科博泰生物科技有限公司 识别N-乙酰-β-D-氨基葡萄糖苷酶的单克隆抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177001A (en) 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor
US5177002A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
US5326749A (en) 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
US5516657A (en) * 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
US5652352A (en) * 1994-03-31 1997-07-29 Amgen Inc. Afamin: a human serum albumin-like gene

Also Published As

Publication number Publication date
EP1443112A3 (en) 2004-11-03
EP1340815A3 (en) 2003-09-17
CA2223940A1 (en) 1996-12-19
AU6253596A (en) 1996-12-30
DE69635346T2 (de) 2006-07-27
ATE307885T1 (de) 2005-11-15
US20020055140A1 (en) 2002-05-09
EP0837932A4 (en) 2001-02-28
WO1996040903A1 (en) 1996-12-19
CN1510147A (zh) 2004-07-07
EP0837932B1 (en) 2005-10-26
CN1191567A (zh) 1998-08-26
NO975771D0 (no) 1997-12-08
JPH11511962A (ja) 1999-10-19
BR9609072A (pt) 2000-10-24
DE69635346D1 (de) 2005-12-01
ES2252756T3 (es) 2006-05-16
NO975771L (no) 1998-01-30
DE69635346T4 (de) 2007-11-08
EP1443112A2 (en) 2004-08-04
EP1340815A2 (en) 2003-09-03
CN1174097C (zh) 2004-11-03
US6410269B1 (en) 2002-06-25
EP0837932A1 (en) 1998-04-29
US5712104A (en) 1998-01-27

Similar Documents

Publication Publication Date Title
NO323155B1 (no) Makrofagaktiverende faktorer avledet fra klonet vitamin D-bindingsprotein
Paterson et al. Ability of the hydrophobic fusion-related external domain of a paramyxovirus F protein to act as a membrane anchor
Culp et al. Regulated expression allows high level production and secretion of HIV-1 gp120 envelope glycoprotein in Drosophila Schneider cells
Amagai et al. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus.
RU2179034C2 (ru) ЛЕЧЕНИЕ В СЛУЧАЕ ДЕФИЦИТА α-ГАЛАКТОЗИДАЗЫ А
US20100184845A1 (en) Myeloid Colony Stimulating Factor and Uses Thereof
Kido et al. Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus
Naim et al. The pro region of human intestinal lactase-phlorizin hydrolase.
JP2000508894A (ja) 細胞外／上皮増殖因子ｈｃａｂａ５８ｘ
US6165794A (en) Suppression of proteolytic activity by dysfunctional protease formation
RU2198218C2 (ru) СПОСОБ КЛОНИРОВАНИЯ СВЯЗЫВАЮЩЕГО ВИТАМИН D3 БЕЛКА (БЕЛКА Gc), СПОСОБ ПОЛУЧЕНИЯ КЛОНИРОВАННОГО ФАКТОРА АКТИВАЦИИ МАКРОФАГОВ, ФАКТОР АКТИВАЦИИ МАКРОФАГОВ (ВАРИАНТЫ), АДЪЮВАНТ (ВАРИАНТЫ), КЛОНИРОВАННЫЙ СВЯЗЫВАЮЩИЙ ВИТАМИН D3 БЕЛОК (Gc-БЕЛОК), КЛОНИРОВАННЫЙ ДОМЕН III СВЯЗЫВАЮЩЕГО ВИТАМИН D3 БЕЛКА (ВАРИАНТЫ)
WO2002033094A1 (en) Antibody inhibiting vplf activity
AU731911B2 (en) Use of a polypeptide as cellular receptor for adenoviruses
WO1996014863A9 (en) Suppression of proteolytic activity by dysfunctional protease formation
Fan et al. Purification and characterization of a recombinant human thyroid peroxidase expressed in insect cells
US20060014143A1 (en) Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
AU784155B2 (en) Myeloid colony stimulating factor and uses thereof
KR19990022316A (ko) 형질전환 성장 인자 알파 ｈｉ
CA2336406A1 (en) Galectin 11
Yang et al. Demonstration of the interaction of transforming growth factor beta 2 and type X collagen using a modified tandem affinity purification tag
AU2012227349B2 (en) Therapy for alpha-galactosidase A deficiency
CN118460615A (zh) 一种腺病毒载体及其在黄斑变性基因治疗中的应用
JPH09124510A (ja) Ｆａｓリガンドの遊離抑制剤及び抑制方法
JP2003000247A (ja) トランスフォーミング増殖因子αＨＩＩ
CA2402839A1 (en) Galectin 11

Legal Events

Date Code Title Description
CB Opposition filed (par. 26,5 patents act)

Opponent name: NOBUTO YAMAMOTO, 1040 66TH AVENUE, PHILADELPHIA, P

Effective date: 20070913

MM1K Lapsed by not paying the annual fees